Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation

Autor: Garrett Jensen, MD, Randa Tao, MD, Cathy Eng, MD, John M. Skibber, MD, Miguel Rodriguez-Bigas, MD, George J. Chang, MD, Y. Nancy You, MD, Brian K. Bednarski, MD, Bruce D. Minsky, MD, Eugene Koay, MD, PhD, Cullen Taniguchi, MD, PhD, Sunil Krishnan, MD, Prajnan Das, MD, MS, MPH

Publikováno v: Advances in Radiation Oncology, Vol 3, Iss 4, Pp 595-600 (2018)

Purpose: Previous studies have reported that hyperfractionated accelerated reirradiation can be used as part of multimodality treatment of locally recurrent rectal cancer with acceptable toxicity and promising outcomes. The purpose of this study was

Externí odkaz: https://doaj.org/article/67c99092f6d944c8835f242e96a7b11f

Reply to S. Boutayeb et al.

Autor: Lou E; Emil Lou, MD, PhD, Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Muhammad Shaalan Beg, MD, University of Texas Southwestern Medical Center, Dallas, TX; Emily Bergsland, MD, University of California San Francisco, San Francisco, CA; Cathy Eng, MD, Vanderbilt-Ingram Cancer Center, Nashville, TN; Alok A. Khorana, MD, Cleveland Clinic, Cleveland, OH; Scott Kopetz, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX; Sam Lubner, MD, University of Wisconsin, Madison, WI; Leonard Saltz, MD, Memorial Sloan Kettering Cancer Center, New York, NY; Veena Shankaran, MD, MS, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA; and S. Yousuf Zafar, MD, MHS, Duke Cancer Institute, Durham, NC., Beg MS; Emil Lou, MD, PhD, Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Muhammad Shaalan Beg, MD, University of Texas Southwestern Medical Center, Dallas, TX; Emily Bergsland, MD, University of California San Francisco, San Francisco, CA; Cathy Eng, MD, Vanderbilt-Ingram Cancer Center, Nashville, TN; Alok A. Khorana, MD, Cleveland Clinic, Cleveland, OH; Scott Kopetz, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX; Sam Lubner, MD, University of Wisconsin, Madison, WI; Leonard Saltz, MD, Memorial Sloan Kettering Cancer Center, New York, NY; Veena Shankaran, MD, MS, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA; and S. Yousuf Zafar, MD, MHS, Duke Cancer Institute, Durham, NC., Bergsland E; Emil Lou, MD, PhD, Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Muhammad Shaalan Beg, MD, University of Texas Southwestern Medical Center, Dallas, TX; Emily Bergsland, MD, University of California San Francisco, San Francisco, CA; Cathy Eng, MD, Vanderbilt-Ingram Cancer Center, Nashville, TN; Alok A. Khorana, MD, Cleveland Clinic, Cleveland, OH; Scott Kopetz, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX; Sam Lubner, MD, University of Wisconsin, Madison, WI; Leonard Saltz, MD, Memorial Sloan Kettering Cancer Center, New York, NY; Veena Shankaran, MD, MS, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA; and S. Yousuf Zafar, MD, MHS, Duke Cancer Institute, Durham, NC., Eng C; Emil Lou, MD, PhD, Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Muhammad Shaalan Beg, MD, University of Texas Southwestern Medical Center, Dallas, TX; Emily Bergsland, MD, University of California San Francisco, San Francisco, CA; Cathy Eng, MD, Vanderbilt-Ingram Cancer Center, Nashville, TN; Alok A. Khorana, MD, Cleveland Clinic, Cleveland, OH; Scott Kopetz, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX; Sam Lubner, MD, University of Wisconsin, Madison, WI; Leonard Saltz, MD, Memorial Sloan Kettering Cancer Center, New York, NY; Veena Shankaran, MD, MS, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA; and S. Yousuf Zafar, MD, MHS, Duke Cancer Institute, Durham, NC., Khorana AA; Emil Lou, MD, PhD, Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Muhammad Shaalan Beg, MD, University of Texas Southwestern Medical Center, Dallas, TX; Emily Bergsland, MD, University of California San Francisco, San Francisco, CA; Cathy Eng, MD, Vanderbilt-Ingram Cancer Center, Nashville, TN; Alok A. Khorana, MD, Cleveland Clinic, Cleveland, OH; Scott Kopetz, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX; Sam Lubner, MD, University of Wisconsin, Madison, WI; Leonard Saltz, MD, Memorial Sloan Kettering Cancer Center, New York, NY; Veena Shankaran, MD, MS, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA; and S. Yousuf Zafar, MD, MHS, Duke Cancer Institute, Durham, NC., Kopetz S; Emil Lou, MD, PhD, Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Muhammad Shaalan Beg, MD, University of Texas Southwestern Medical Center, Dallas, TX; Emily Bergsland, MD, University of California San Francisco, San Francisco, CA; Cathy Eng, MD, Vanderbilt-Ingram Cancer Center, Nashville, TN; Alok A. Khorana, MD, Cleveland Clinic, Cleveland, OH; Scott Kopetz, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX; Sam Lubner, MD, University of Wisconsin, Madison, WI; Leonard Saltz, MD, Memorial Sloan Kettering Cancer Center, New York, NY; Veena Shankaran, MD, MS, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA; and S. Yousuf Zafar, MD, MHS, Duke Cancer Institute, Durham, NC., Lubner S; Emil Lou, MD, PhD, Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Muhammad Shaalan Beg, MD, University of Texas Southwestern Medical Center, Dallas, TX; Emily Bergsland, MD, University of California San Francisco, San Francisco, CA; Cathy Eng, MD, Vanderbilt-Ingram Cancer Center, Nashville, TN; Alok A. Khorana, MD, Cleveland Clinic, Cleveland, OH; Scott Kopetz, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX; Sam Lubner, MD, University of Wisconsin, Madison, WI; Leonard Saltz, MD, Memorial Sloan Kettering Cancer Center, New York, NY; Veena Shankaran, MD, MS, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA; and S. Yousuf Zafar, MD, MHS, Duke Cancer Institute, Durham, NC., Saltz L; Emil Lou, MD, PhD, Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Muhammad Shaalan Beg, MD, University of Texas Southwestern Medical Center, Dallas, TX; Emily Bergsland, MD, University of California San Francisco, San Francisco, CA; Cathy Eng, MD, Vanderbilt-Ingram Cancer Center, Nashville, TN; Alok A. Khorana, MD, Cleveland Clinic, Cleveland, OH; Scott Kopetz, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX; Sam Lubner, MD, University of Wisconsin, Madison, WI; Leonard Saltz, MD, Memorial Sloan Kettering Cancer Center, New York, NY; Veena Shankaran, MD, MS, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA; and S. Yousuf Zafar, MD, MHS, Duke Cancer Institute, Durham, NC., Shankaran V; Emil Lou, MD, PhD, Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Muhammad Shaalan Beg, MD, University of Texas Southwestern Medical Center, Dallas, TX; Emily Bergsland, MD, University of California San Francisco, San Francisco, CA; Cathy Eng, MD, Vanderbilt-Ingram Cancer Center, Nashville, TN; Alok A. Khorana, MD, Cleveland Clinic, Cleveland, OH; Scott Kopetz, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX; Sam Lubner, MD, University of Wisconsin, Madison, WI; Leonard Saltz, MD, Memorial Sloan Kettering Cancer Center, New York, NY; Veena Shankaran, MD, MS, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA; and S. Yousuf Zafar, MD, MHS, Duke Cancer Institute, Durham, NC., Zafar SY; Emil Lou, MD, PhD, Masonic Cancer Center, University of Minnesota, Minneapolis, MN; Muhammad Shaalan Beg, MD, University of Texas Southwestern Medical Center, Dallas, TX; Emily Bergsland, MD, University of California San Francisco, San Francisco, CA; Cathy Eng, MD, Vanderbilt-Ingram Cancer Center, Nashville, TN; Alok A. Khorana, MD, Cleveland Clinic, Cleveland, OH; Scott Kopetz, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX; Sam Lubner, MD, University of Wisconsin, Madison, WI; Leonard Saltz, MD, Memorial Sloan Kettering Cancer Center, New York, NY; Veena Shankaran, MD, MS, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA; and S. Yousuf Zafar, MD, MHS, Duke Cancer Institute, Durham, NC.

Publikováno v: JCO oncology practice [JCO Oncol Pract] 2020 Aug; Vol. 16 (8), pp. 525. Date of Electronic Publication: 2020 Jun 23.